Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial

Affiliations

• ¹ Department of Clinical Haematology, The Alfred Hospital, Melbourne, Victoria, Australia.
• ² Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia.
• ³ Ulm University Hospital, Ulm, Germany.
• ⁴ Indiana University Cancer Center, Indianapolis, Indiana, USA.
• ⁵ The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ⁶ Hospital Universitario y Politécnico La Fe, Valencia, Spain.
• ⁷ Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
• ⁸ Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.
• ⁹ AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium.
• ¹⁰ HUS Comprehensive Cancer Center, Hematology Research Unit Helsinki and iCAN Digital Precision Cancer Center Medicine Flagship, University of Helsinki, Helsinki, Finland.
• ¹¹ Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
• ¹² University of Kansas Cancer Center, Kansas City, Kansas, USA.
• ¹³ Bristol Myers Squibb, Summit, New Jersey, USA.
• ¹⁴ BMS Center for Innovation and Translational Research Europe (CITRE, a Bristol-Myers Squibb Company), Seville, Spain.
• ¹⁵ Weill Cornell Medicine, New York, New York, USA.
• ¹⁶ New York Presbyterian Hospital, New York, New York, USA.